Digestive Disease Center, Showa University, Northern Yokohama Hospital, Yokohama, Japan.
Gastrointest Endosc. 2013 Aug;78(2):250-7. doi: 10.1016/j.gie.2013.01.008. Epub 2013 Feb 27.
Recent technological advances have allowed superficially spreading intramucosal carcinomas of the esophagus to be successfully resected by circumferential endoscopic submucosal dissection (cESD). After this procedure, esophageal strictures develop in most patients and are mainly treated by endoscopic balloon dilation (EBD).
To compare oral steroids plus EBD with EBD alone for the management of benign esophageal strictures after cESD.
Retrospective cohort study.
Tertiary-care referral center.
We studied 23 consecutive patients who underwent complete cESD for superficial esophageal carcinoma (22 squamous cell carcinomas and 1 adenocarcinoma associated with Barrett's esophagus).
After cESD, patients were managed with EBD alone (EBD, n = 13) or with EBD and oral prednisolone (steroid + EBD, n = 10), 30 mg daily, started 2 days after cESD and gradually tapered and discontinued after 8 weeks.
Total number of EBD sessions and total EBD period (months).
Steroid + EBD patients required fewer sessions (13.8 ± 6.9 vs 33.5 ± 22.9; P < .001) and a shorter management period (4.8 ± 2.3 vs 14.2 ± 17.5 months, P = .005) compared with the EBD group. An additional 3 patients received oral steroids a mean interval of 158 days after cESD. These patients required more EBD sessions (46.3 ± 30.0; P = .002), and the EBD period was significantly longer (17.5 ± 13.0 months; P = .005) than in the early steroid + EBD group.
Nonrandomized study; retrospective analysis.
After cESD, oral steroid therapy dramatically reduced the need for EBD. We conclude that oral steroid therapy after EBD is an effective strategy for the management of esophageal strictures after complete cESD.
最近的技术进步使得食管黏膜内浅表扩散型癌能够通过环形内镜黏膜下剥离术(cESD)成功切除。在该手术之后,大多数患者会出现食管狭窄,并主要通过内镜球囊扩张(EBD)进行治疗。
比较口服类固醇联合 EBD 与单纯 EBD 治疗 cESD 后良性食管狭窄。
回顾性队列研究。
三级转诊中心。
我们研究了 23 例连续接受 cESD 治疗的浅表性食管癌患者(22 例为鳞状细胞癌,1 例为与 Barrett 食管相关的腺癌)。
cESD 后,患者接受单纯 EBD 治疗(EBD 组,n = 13)或 EBD 联合口服泼尼松龙治疗(类固醇+EBD 组,n = 10),剂量为 30 mg/d,于 cESD 后 2 天开始逐渐减量并在 8 周后停药。
EBD 总次数和总 EBD 时间(月)。
与 EBD 组相比,类固醇+EBD 组所需的 EBD 次数更少(13.8 ± 6.9 次 vs. 33.5 ± 22.9 次;P <.001),EBD 管理时间更短(4.8 ± 2.3 个月 vs. 14.2 ± 17.5 个月,P =.005)。另有 3 例患者在 cESD 后平均 158 天接受了口服类固醇治疗。这些患者需要更多的 EBD 次数(46.3 ± 30.0 次;P =.002),EBD 时间明显更长(17.5 ± 13.0 个月;P =.005)。
非随机研究;回顾性分析。
cESD 后,口服类固醇治疗显著减少了 EBD 的需求。我们的结论是,EBD 后口服类固醇治疗是治疗 cESD 后完全性食管狭窄的有效策略。